Takeda Pharmaceutical dividend and valuation
Valuation
Takeda Pharmaceutical paid ¥202.00 per share in dividends over the last 12 months (yield 2.9%). Next ex-dividend date: March 30, 2027. The P/E ratio is 312.4. The average price target of 16 analysts is ¥7,118.94.
Data as of November 21, 2026
Takeda Pharmaceutical compared with similar companies
Takeda Pharmaceutical's P/E (trailing 12 months): 312.4, +657% against the median of a group of 11 similar companies (41.2).
| Metric | Takeda Pharmaceutical | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 312.4 | 41.2 | 26.8 – 83.7 | High |
| Forward P/E | 49.7 | 30.9 | 23.6 – 50.6 | Middle |
| EV/EBITDA | 11.8 | 24.6 | 17.9 – 39.4 | Low |
| Price/book | 1.50 | 4.64 | 3.35 – 11.9 | Low |
| Price/sales | 2.37 | 9.50 | 4.06 – 14.2 | Low |
| Gross margin | 64.8% | 75.9% | 64.1% – 84.0% | Middle |
| Operating margin | 16.6% | 24.1% | 19.7% – 32.8% | Low |
| Net margin | 0.9% | 17.8% | 13.0% – 32.2% | Low |
| ROE | 0.6% | 15.2% | 13.5% – 19.8% | Low |
| Debt/equity | 0.72 | 0.11 | 0.02 – 0.44 | High |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Takeda Pharmaceutical: valuation over time
The dividend yield (2.9%) is below the median of the last 10 fiscal years (4.3%).
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| Mar 2026 | ¥5,664.00 | -¥96.75 | — | ¥200.00 | 3.5% |
| Mar 2025 | ¥4,413.00 | ¥67.23 | 65.6 | ¥196.00 | 4.4% |
| Mar 2024 | ¥4,183.00 | ¥91.16 | 45.9 | ¥188.00 | 4.5% |
| Mar 2023 | ¥4,350.00 | ¥201.94 | 21.5 | ¥180.00 | 4.1% |
| Mar 2022 | ¥3,498.00 | ¥145.87 | 24.0 | ¥180.00 | 5.1% |
| Mar 2021 | ¥3,985.00 | ¥238.96 | 16.7 | ¥180.00 | 4.5% |
| Mar 2020 | ¥3,308.00 | ¥28.25 | 117.1 | ¥180.00 | 5.4% |
| Mar 2019 | ¥4,521.00 | ¥139.82 | 32.3 | ¥180.00 | 4.0% |
| Mar 2018 | ¥5,183.00 | ¥237.56 | 21.8 | ¥180.00 | 3.5% |
| Mar 2017 | ¥5,229.00 | ¥146.26 | 35.8 | ¥180.00 | 3.4% |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- ¥11.14T
- Enterprise value
- ¥16.08T
- PEG
- 0.49
- EV/revenue
- 3.43
Profitability and growth
- ROA
- 3.3%
- ROIC
- 3.9%
- Revenue growth (year over year)
- 6.7%
- Earnings growth (year over year)
- -1,687.1%
Financial health
- Total cash
- ¥418.53B
- Total debt
- ¥5.36T
- Current ratio
- 1.15
- Quick ratio
- 0.51
- Altman Z-Score
- 1.21
- Piotroski F-Score
- 6.00
Dividends
- Annual dividend per share
- ¥202.00
- Dividend yield
- 2.9%
- Payout ratio
- 905.0%
- Ex-dividend date
- March 30, 2027
Analysts and estimates
- Average price target
- ¥7,118.94
- Median price target
- ¥7,250.00
- High price target
- ¥8,400.00
- Low price target
- ¥5,800.00
- Analysts with a price target
- 16
- Consensus
- Buy
- Forward EPS
- ¥140.39
- EPS estimate, current year
- ¥139.71
Shares and trading
- Beta
- 0.08
- Average volume
- 4.51M
- Shares outstanding
- 1.6B
- Float
- 1.58B
- Institutional ownership
- 49.0%
- Insider ownership
- 1.2%
